VLA-1 Antagonist Therapy for Stroke Ischemic Damage Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for stroke, traumatic brain injury, and spinal cord injury lack effective methods to reduce ischemic damage and improve outcomes, with existing therapies often having limited efficacy in minimizing infarct size and improving symptoms.
Innovation Solution
Administration of a VLA-1 antagonist, such as a VLA-1 antibody or peptide, which inhibits the interaction between VLA-1 and its ligands, thereby reducing ischemic injury by blocking VLA-1 activity and modulating cell signaling, thereby reducing infarct size and improving symptoms in neuronal tissue, brain, and spinal cord.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing stroke treatments are used, then standard care is provided, but efficacy in reducing infarct size and improving outcomes is limited
Solution Approach 1:
The patent introduces a VLA-1 antagonist as an intermediary substance that blocks the interaction between VLA-1 integrin and its ligands (collagen, laminin). This mediator prevents pathological cell adhesion and signaling processes that contribute to ischemic damage, thereby improving treatment efficacy without directly affecting the core stroke pathology
Solution Approach 2:
The invention changes the biochemical parameter of cell adhesion strength by modulating VLA-1 activity. By administering VLA-1 antagonists, the patent alters the binding affinity between integrins and extracellular matrix components, thereby changing the physiological parameters of cell signaling and adhesion to reduce infarct size and improve outcomes
2Reliability
If VLA-1 antagonist is administered, then ischemic damage is reduced and infarct size is minimized, but the complexity of treatment increases
Solution Approach 1:
The patent extracts and targets a specific pathological mechanism (VLA-1 mediated adhesion and signaling) from the complex cascade of events following stroke. By isolating and blocking this single key pathway with a specific antagonist, the treatment achieves efficacy while maintaining relative simplicity compared to addressing all downstream effects of ischemia
Solution Approach 2:
The invention segments the complex stroke pathology into discrete targetable pathways, focusing specifically on the VLA-1 integrin pathway. This segmentation allows for targeted intervention at a specific point in the disease cascade, simplifying the overall treatment approach while maintaining high efficacy in reducing ischemic damage
Data Source
AI summary
Methods and compositions for treating stroke are disclosed.